Moderna: EMA approves marketing of Omicron vaccine

(CercleFinance.com) - Moderna today announced that the European Medicines Agency (EMA) has accepted a variation for the evaluation of a 50 µg booster dose of the COVID bivalent booster vaccine candidate containing Omicron, mRNA-1273.
222 in people aged 12 and older.

This is a new generation bivalent vaccine containing 25µg of mRNA-1273 (Spikevax) and 25µg of a candidate vaccine targeting the relevant Omicron variant.

The group said that its vaccine, which targets the BA.4/BA.5 Omicron sub-variants will now provide a second option to help protect people across Europe as the winter months approach.


Copyright (c) 2022 CercleFinance.com. All rights reserved.